On June 4, 2025, NovoCure Ltd. held its annual general meeting where shareholders elected 11 directors and approved a compensation plan for executives, including 179,426 stock units awarded to Francis Leonard with vesting conditions. The voting represented 83.4% of total shares, illustrating strong shareholder participation.